

PATENT

Examiner:

Group Art Unit:

Our Docket: P41 90004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wahl and O'Gorman

Serial No.: 08/486,409

June 7, 1995 Filed:

For: FLP-MEDIATED GENE MODIFICA-

> TION IN MAMMALIAN CELLS, AND COMPOSITIONS AND CELLS

USEFUL THEREFOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trade-

Unassigned

marks, Washington, D.C. 20231 on

Unassigned

Date of Signature

BOX SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

In the Specification

On page 11, line 30 insert -- (SEQ ID NO:3) --.

On page 17, line 37 insert -- (SEQ ID NO:4) --.

On page 28, line 12 insert the following paragraphs:

--Sequence I.D. No. 3 is the nucleotide sequence of the FLP recombination target site (FRT).

Sequence I.D. No. 4 is the nucleotide sequence of the oligonucleotide used in the construction of pFTGRGAL. --